AR & VR in Healthcare Market SWOT Analysis, Key Players, Analysis and Forecasts Till 2027

 Market Highlights

The AR & VR in healthcare market is expected to grow at an approximate CAGR of 30.2% during forecast period, 2022–2027.

Rising demand to reduce healthcare cost is one of the key factors driving the AR & VR in healthcare market. For instance, with the use of AR navigation system nearly USD 288 million can be saved on minimally-invasive surgical procedures in the US.

Various other factors such as rising government funding, high prevalence of chronic diseases, rising adoption of AR and VR in fitness management, increasing penetration of connected devices in the healthcare sector, and rising awareness about VR therapy are also expected to propel the growth of the market.

However, concerns regarding data privacy, lack of expertise among medical practitioners, and lack of competence in deployment of the AR and VR solutions can hinder the market growth over the forecast period.

Key Players

Some of the key players in the AR & VR in healthcare market are Atheer, Augmedix, Daqri, Firsthand Technology, Google, Medical Realities, Microsoft, Mindmaze, Oculus VR, Psious, EchoPixel, Inc., Osso VR Inc., SURGICAL THEATER, LLC, Orca Health, Inc., Hologic Inc., 3D Systems, Inc., and others.

Segmentation

The AR & VR in Healthcare Market is segmented based on technology, offering, device type, application, end user, and region.

The global market for virtual and augmented reality in healthcare is segmented into AR technology and VR technology. The AR technology segment is further classified as marker-based AR and markerless AR. The marker-based AR segment includes passive marker, and active marker. The markerless AR segment includes model-based tracking, and image processing-based tracking. The VR technology segment is further classified as nonimmersive technology, and semi-immersive and fully immersive technologies.

Based on offering, the market is segmented into hardware components and software. The hardware components segment is further classified as sensors, semiconductor component, displays and projectors, position tracker, cameras, and others. The sensors segment includes accelerometer, gyroscope, magnetometer, and proximity sensor. The semiconductor component segment includes controller/processor, and integrated circuits. The software segment is further classified as software development kits, and cloud-based services.

Based on device type, the market is segmented into AR device type, and VR device type. The AR device type segment is further classified as head-mounted display, and handheld device. The VR device type segment is further classified as head-mounted display, gesture-tracking device, and projectors and display walls. The gesture-tracking device segment includes data gloves, and others.

Based on application, the market is segmented into fitness management, patient care management, surgery, pharmacy management, medical training and education, and others.

Based on end user, the market is segmented into hospitals & clinics, surgical centres, pharmaceutical companies, research and academic institutes, and others.

Regional Analysis

The Americas dominated the global market for AR & VR in healthcare owing to the rising demand to reduce healthcare cost and presence of major market players.

In 2017, it was estimated that Europe stood second in the AR & VR in healthcare market. This can be attributed to the rising funding for innovation and increasing technological advancements. For instance, the European Union’s Horizon 2020 programme is allocating nearly USD 91.51 billion of funding over seven years for research and innovation.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and high prevalence of chronic diseases drives the regional markets of the Asia Pacific region.

On the other hand, the Middle East and Africa held least share in the AR & VR in healthcare market due to the low per capita income and stringent government policies, especially within the African region.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Sparkling Key Players Shares, Revenue, Analysis and Forecasts to 2027

 Market Highlights

It is estimated that the global IPF treatment market is expected to register a CAGR of 12.3% during the forecast period of 2022 to 2027, with a market value of USD 2,237 million in 2022.

IPF is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. However, the high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment market.

The global idiopathic pulmonary fibrosis market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in September 2022, FibroGen, Inc. announced that the grant of Fast Track designation by US Food and Drug Administration (FDA) for the company’s anti-CTGF antibody, Pamrevlumab, for the treatment of patients with IPF.

Key Players

Some of the key players in the global IPF treatment market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibrogen, Inc., Cipla, Merck & Co., Inc., Prometic Life Sciences Inc., and others.

Segmentation

The global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market has been segmented based on treatment.

The market, based on treatment, has been further divided into drug class, oxygen therapy, lung transplant, and others. The drug class segment is likely to hold a major share in the market due to the increasing adoption of the drugs for the treatment of IPF and wider preferability. The oxygen therapy segment is predicted to be the fastest growing due to the increasing inclination of medical professionals towards this therapy for the treatment of IPF.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The IPF treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European IPF treatment market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The IPF treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Lupus Market Share Analysis, Strategies, Revenue and Forecasts to 2027

 Market Overview

The global Vitamin K2 market is expected to develop at a CAGR of 7.1 percent (2021-2028). Factors such as rising demand for healthy foods and supplements, rising cases of cardiovascular disease and osteoporosis, and a rise in the global elderly population base will all contribute to the growth.

Vitamin K is a fat-soluble vitamin that aids in the coagulation of blood. Vitamin K is necessary for bone health and the prevention of osteoporosis. Vitamin K (K0) and Vitamin K (K1) are the two subtypes (K). Although their attributes differ depending on the type, both types have synthetic forms. Phylloquinone (K) and menaquinone (M) are the most relevant variations in this context (MK-n).

List of Key Companies Covered in this report:

• Kappa Bioscience (Norway)
• Lesaffre (France)
• Viridis BioPharma (India)
• Seebio Biotech (Shanghai) Co.,Ltd (China)
• DSM (Netherlands)
• International Flavors & Fragrances Inc. (US)
• Kyowa Hakko Bio Co. Ltd (Japan)
• Purayati (India)
• Vox Nutrition (US)
• Anderson Global Group, LLC. (US)

Market Segmentation

Based on Type, the Vitamin K2 Market is segmented into MK-4, MK-7, Other.

MK-7:

MK-seven is a vitamin K subtype. Menaquinone (shortened MK-n or MenaQ) is another name (the q means quinine). This is required for the production of prothrombin within the body. Since vitamin K is involved in blood clotting, a vitamin K shortage can induce bleeding difficulties.

MK-4:

MK-4 is a kind of Vitamin K that is found in animal tissues naturally. This is sold as a dietary supplement to treat osteoporosis, diabetes-related eye problems, vitamin D deficiency, bone fractures, and age-related macular degeneration (AMD).

The market is divided into Powder and Oil segments based on application.

Powder:

Vitamin K is a powdered vitamin that is used to treat excessive calcium levels. The vitamin assists your body to absorb less calcium, which might minimize your risk of developing osteoporosis or kidney stones. Vitamin K is also used to stop and slow bleeding caused by blood-thinning drugs (anticoagulants) like warfarin.

Oil:

Vitamin K is mostly available in supplements. However, it can also be found in dietary oils for cooking. Plants that produce vitamin K oil are produced on terrain that is rich in particular minerals and nutrients. Plants can create more vitamins within that type of soil than they could if they were growing in a nutrient-deficient condition.

Industry News

The function of vitamins in general health and their benefits on the human body, particularly bones, is well supported by clinical research. Vitamin k-based goods, such as injection form (pharmaceutical grade), food fortification, oral supplements, and dietary supplements, will benefit from this aspect. Because of the rising demand for vitamin supplements, the worldwide Vitamin K market is likely to rise significantly over the forecast period.

Vitamin K injections, which are more expensive than other kinds of vitamin supplementation, could manage vitamin K deficiency. Over the projected period, this aspect will restrain the growth of the Vitamin K injection market. The market for vitamin K, on the other hand, is predicted to rise due to the rising demand for organic foods, which encompasses dairy products.

Regional Classification

North America is the greatest market shareholder in 2019, followed by Europe and the Asia Pacific. Within the next 5 years, the demand for vitamin K2 in the Asia Pacific is projected to increase due to a significant increase in the consumption of functional foods by inhabitants of Australia, India, and China. Because of the government's ongoing health and wellness efforts, the Middle East and Africa are likely to have a moderate demand for vitamin K2.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Lupus Market Advanced Technologies, Industry Size, Iconic Revenue, Shares, Trends and Demand 2027

 Overview:

Lupus is a chronic autoimmune disease which occurs when the immune system attacks the healthy cells and tissues of the body, thereby causing inflammation, pain, swelling, and damage throughout the body. Many people have an inherit tendency towards developing or attaining lupus, which can be triggered due to certain drugs, infections, or even sunlight. The prevalence of this condition has prompted Market Research Future (MRFR) to take notice and study the global market of the same. As of 2022, the market valuation of Lupus stood at USD 1.48 billion. However, as per the latest studies, the global lupus market is projected to grow significantly during the forecast period with a CAGR of 11.2%.

Various factors such as the growing prevalence of lupus diseases, increasing R&D activities, and continuing medical advancements for the treatment of systemic lupus erythematosus are all identified as key factors driving the growth of the market. Also, the market involves a number of noteworthy companies that are involved in the development of new products and product launches. However, irrespective of the market drivers, constraints such as strict government regulation and rising prices of lupus drugs can severely hamper its market growth during the review period.

Competitive Landscape

The global lupus market holds a number of noteworthy players, including Merck KGaA, Cadila Healthcare, Mylan N.V., F. Hoffmann-La Roche AG, Aurinia Pharmaceuticals, Inc., GlaxoSmithKline PLC, Eli Lily and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Lycera Corporation, and Sanofi.

Dec 11th, 2022, Neovacs, a pioneer in the field of active immune therapy for treating autoimmune diseases, announced the continuation of its partnership with Centurion Pharma in Lupus (SLE). This is based on the study results of the Phase IIb trial with IFNalpha Kinoid.

Market Segmentation

The Lupus Market segmentation is done on the basis of treatment, end-user, and types.

By treatment, the market includes antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, immunosuppressants, and others.

By end-user, the market divides into diagnostic laboratories, hospitals and clinics, and others.

Lastly, by type, the market comprises cutaneous lupus erythematosus, systemic lupus erythematosus, neonatal lupus, and drug-induced lupus erythematosus. The lupus erythematosus market segment is projected to hold the largest market percentage due to the increasing prevalence of such diseases and the increasing drug development over the years.

Regional Analysis

The global lupus market is geographically segmented into the following regions: Americas, Asia Pacific, Europe, and the Middle East & Africa.

The Americas is anticipated to be the most dominant regional market due to a number of factors. This includes the growing prevalence of lupus diseases, rising demand for better treatment options, favorable government initiatives, and the availability of reimbursement. In addition to these, the established healthcare infrastructure facility coupled with the accessibility to biologics are also expected to propel the market growth of this region.

The European market is believed to hold the second-largest market position following the Americas. The growth of the market herein is attributed to the expanding R&D activities and widespread prevalence of lupus diseases.

The Asia-Pacific region is expected to be the fastest-growing regional market. This can be attributed to the growing healthcare sector, the rising incidences of lupus diseases, and increasing regional expansion by prominent market players.

The Middle East & Africa region holds the least market share among all the mentioned regions.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Ultrasound Probe Disinfection Market Overview | Major Vendors Demand | 2022 Analysis and Forecasts Till 2027

 Market Highlights

The Ultrasound Probe Disinfection Market is expected to witness tremendous growth owing to the rising demand for disinfectant probes in hospitals, increasing cases of bacterial infection in healthcare center during the treatment, and increasing implementation of high-level disinfection process for critical ultrasound probes. The global ultrasound probe disinfection market was estimated USD 314.1 million in 2022 and expected to reach USD 819.1 million by 2027 at a healthy CAGR of 21.1% by 2027.

However, factors such as high cost of switching, maintenance cost for the ultrasonic instrument may hinder the market growth during the forecast period.

Key Players

Some of the key players in the global ultrasound probe disinfection market are STERIS (UK), Nanosonics (Australia), Tristel (UK), Ecolab (US), Schülke & Mayr (Germany), Advanced Sterilization Products (US), CIVCO Medical Solutions (US), Germitec (France), Parker Laboratories (US), CS Medical (US), Virox Technologies (Canada), and Metrex Research (US).

Segmentation

The Global Ultrasound Probe Disinfection Market is segmented on the basis of product, probe type, by process and end-user. The ultrasound probe disinfection market, by product, is segmented into instrument, service, and consumables. The instrument is segmented into automated probe reprocessors, UV-C disinfectors, manual reprocessors/soaking stations, and ultrasound transducer storage cabinets. The consumables are sub-segmented into formulation, type of disinfectants, and detergents. The disinfectants, by formulation, is segmented into disinfectant wipes, disinfectant liquids, and disinfectant sprays. By type, consumables are segmented into high-level disinfectants, and intermediate/low-level disinfectants and detergents are segmented into enzymatic detergents and non-enzymatic detergents.

By probe type the market is segmented into linear transducers, convex transducers, phased array transducers, endocavitary transducers, transesophageal echocardiography transducers| (TEE), and other. On the basis of process, the market is segmented into high-level disinfection and intermediate/low-level disinfection. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, ambulatory care centers, academic & research institutes, and others.

Regional Analysis

The Americas leads in the market owing to the increasing prevalence of rising incidence of bacterial infection, increasing research & development in ultrasound probe disinfection and growing healthcare expenditure. According to the Consumer Report Organization and Centers for Disease Control and Prevention (CDC) July 2015 publication, it is estimated that every year approximately 648,000 patients in the US got infected by bacteria during a hospital stay, and around 75,000 died. The increasing incidences of bacterial infection may support this market positively.

Europe is the second largest ultrasound probe disinfection systems market during the forecast period due to increasing prevalence of human papillomavirus (HPV). The human papillomavirus is a skin to skin transmitted disease. According to the Oxford Vaccine group fact sheet, HPV infection causes cervical cancers. It was also reported that 99% of cervical cancers are caused by the Human Papillomavirus (HPV) infection. Furthermore, it was also maintained that 3,126 new cases of cervical cancer were reported in the UK in 2015. The increasing prevalence of HPV infection supports the market growth in this region.

Asia-Pacific was estimated to be the fastest growing region for the global ultrasound probe disinfection market in 2022. The market is expected to witness high growth owing to the rising prevalence of bacterial infections. The Middle East and Africa holds the low share for this market. However, the rising healthcare awareness at the hospital and in the community are expected to influence the market positively.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Soft Tissue Sarcoma Market Professional Survey about Therapeutics and Pipeline Review 2022

 Market Highlights

Soft Tissues Sarcoma is the rare and diverse group of cancers that develop from tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma that are identified, the common types of soft tissue sarcoma include liposarcomas, leiomyosarcomas, and others. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumor. If surgical procedure is not required, chemotherapy can be used alone.

Some of the major driving factors includes increasing research and development on biological and targeted drug therapies for the cancer treatment along with the expiration of patents. The increasing healthcare expenditure for quality patient care and various advanced treatments also boost the growth of the global soft tissue sarcoma treatment market. In addition, increasing focus on personalized medicine along with huge investments for anti-cancer treatment research is likely to unveil new paths for soft tissue sarcoma treatment market in the near future.

Key Players

Some of key the players in the global Soft Tissue Repair Market are GlaxoSmithKline plc. (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.

Segmentation

The Soft Tissue Sarcoma Market is segmented on the basis of treatment, disease type, distribution channel, and end-users.

On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcategorized into internal radiation therapy and external radiation therapy. On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma. On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and other. On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

Regional Analysis

Global soft tissue sarcoma consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

Americas is expected to lead the global market due to high incidence of cancer and soft tissue sarcoma. According to the American Cancer Society, more than 11,400 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. While, Europe is expected to hold the second largest market share in the global market. Market in Asia Pacific region is expected to witness significant growth owing to increasing case of cancer and growing awareness regarding advanced cancer treatments. In addition, increasing healthcare expenditure related to cancer and associated disease is expected to boost the market growth in near future.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Erectile Dysfunction Drugs Market Expected to Highest Grow by 2022 To 2027

 Erectile Dysfunction Drugs Market - Key Players                   

Pfizer Inc. (U.S), Bayer AG (Germany), Eli Lily & Co. (U.S), Dong–A Pharmaceutical Co. Ltd. (South Korea), Apricus Biosciences Inc.(U.S), S.K. Chemicals Co. Ltd. (South Korea), Apricus Biosciences Inc. (U.S), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Dong-A Pharmaceutical Co. Ltd., (South Korea), Meda Pharmaceuticals, Inc. (U.S),  Vivus, Inc. (U.S),  and others are some of the prominent players at the forefront of competition in the global erectile dysfunction drugs market and are profiled in MRFR Analysis. 

Global Erectile Dysfunction Drugs Market - Scenario

Inability to keep firm erection firm enough during sexual intercourse in known as erectile dysfunction. It is also known as impotence. It is a common medical disorder primarily affecting men older than 40 years of age. Stress and mental health concerns may worsen the problem of erectile dysfunction. Physical and psychological issues may also cause erectile dysfunction.

There is also an increase in the competition among the major market players. Patent expiry of number of blockbuster drugs, availability of counterfeit drugs and increasing manufactures of generic drugs in the market may result in the decline of erectile dysfunction drugs market.

Global market of erectile dysfunction drugs is expected to reach USD 2.95 billion in 2027 from USD 1.65 billion in 2022 with a CAGR of approximately 6.5% during the forecast period 2022-2027.

Global Erectile Dysfunction Drugs Market – Segmentation

Global Erectile Dysfunction Drugs Market has been segmented on the basis of product which includes Viagra, Cialis, Levitra, Stendra, Zydena and other drugs and on the basis of end users the market is segmented into Hospitals, clinics, pharmaceutical companies and others.

Global Erectile Dysfunction Drugs Market - Regional Analysis

Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas account for the major share of the market owing to the presence of patient population, well-developed technology, and high healthcare expenditure. According to University of Wisconsin Hospitals and Clinics Authority, about 5 percent of men that are 40 years old have complete erectile dysfunction pills, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.

Europe holds the major share of the market, which is majorly contributed by Germany, the U.K., and France. According to the UK Health Centre, 50 percent of men that smoke a pack of cigarettes a day have a higher chance of developing erectile dysfunction. Furthermore, as per a study recently presented at the European Association of Urology showed that erectile dysfunction isn’t being treated very often, with only 25.4 percent of men in the being treated for the condition.

Asia Pacific is the fastest growing market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Cell Lysis and Disruption Market Regional Outlook, End User, Top Key Players, Competitors, Share Analysis and Forecast to 2027

 Market Forecast

Registering a CAGR of 8.6%, the Global Cell Lysis & Disruption Market is expected to reach USD 5.7 Billion in by 2025.

 The expanding biotechnology and biopharmaceutical sector are driving the growth of this market. For instance, firms in the U.S. firms perform extensive R&D in pharmaceuticals which is approximately USD 75 billion. 

The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Thermo Fisher Scientific acquired Gatan, Inc. from Roper Technologies for approximately USD 925 million.

Market Influencers

The rising focus on personalized medicine would directly drive the growth of the global cell lysis & disruption market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to positively affect market growth during the forecast period.  

Key Players

• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• Thermo Fisher Scientific, Inc. (US)
• Miltenyi Biotec (Germany)
• Merck KGAA (Germany)
• Qsonica, LLC (US)
• Becton Dickinson & Company (US)
• Cell Signaling Technology, Inc. (US)
• Hoffmann–La Roche Ltd (Switzerland)
• Qiagen N.V. (Netherlands)

Segmentation

The global Cell Lysis & Disruption Market has been segmented into technique, product, cell type, and end user.

By technique, the market has been segregated into reagent based and physical disruption. The reagent based segment has been further sub-segmented into detergent and enzymatic. The physical disruption further divided into mechanical homogenization, ultrasonic homogenization, pressure homogenization, and temperature treatments

By product, the market has been bifurcated into consumables and instruments. The consumables segment is estimated to hold major market share in the market due to the rise in funding of cell based research. Consumables has been further divided into reagent and kits, beads and disposables. The instrument segment has been further categorized as sonicators, homogenizers, French press, microfluidizer, and others. 

On the basis of cell type, the global cell lysis & disruption market has been classified as mammalian cells, microbial cells, and others.

The global cell lysis & disruption market, by end user, has been divided into research laboratories and institutes, pharmaceutical and biotechnology companies, and others.

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global cell lysis & disruption market owing to the growing clinical R&D budgets by both governments as well as public and private organizations in the pharmaceutical and biotech sector and increasing demand for novel therapeutics in the region.  Additionally, the rising prevalence of geriatric population along with various chronic diseases is contributing to the growth of this market. According to a report by the Population Reference Bureau, the number of older population (aged 65 and above) will rise to nearly 24% from 15% by 2060. Europe is expected to hold the second-largest position in the global cell lysis & disruption cell lysis buffer market owing to the presence of a strong academic & research base and availability of funding for research in the European countries. Moreover, rising healthcare expenditure is boosting the market in this region. Asia-Pacific is anticipated to be the fastest-growing region is due to the growing interest of major key players in emerging markets and rapidly developing healthcare infrastructure in this region. The Middle East & Africa has the least share of the global cell lysis & disruption market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector. 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Automated Hospital Beds Market Global Market by Treatments, Causes, Drugs and Diet 2022-2027

 Automated Hospital Beds Market Overview

The global automated hospital beds market is reported to grow at a steady and decent pace as per the recently released report by Market Research Future (MRFR). The market is expected to jump from its 2022 valuation of USD 1,590.1 million to reach a valuation of 2,553.4 million by 2027. The global market is expected to grow at a compound annual growth rate of 5.97% during the forecast period between 2022 and 2027.

Patients in hospitals experience difficulty in getting in and out of their assigned beds due to their condition or health status. Automated hospital beds play a significant role in solving this major problem. These automated beds aid patients to easily sit and get out of their beds with comfort and little to no effort. Add to this, the beds are extremely beneficial for both the doctors and the nurses while performing vital treatments or procedures upon the patients. The global market is influenced by a rising number of chronic and acute illness, increasing obese population, growing geriatric population, rising healthcare expenditure, and constantly developing design and technology of hospital beds. However, the high cost associated with such beds can hamper its global market growth during the forecast period.

Competitive Landscape

The global automated hospital beds market comprises a number of prominent players who strive to ensure optimal patient satisfaction and develop new technologies to help the market grow further. Some of the major players identified in the market are Medline Industries, Inc., ArjoHuntleigh, Linet spol. s r.o., Gendron Inc., Hill-Rom, Paramount Bed Holdings Co., Ltd., Invacare Corporation, Stryker, and others.

December 10th, 2022, Hill-Rom, a leading provider of medical technologies specializing in developing hospital beds, announced in a statement about its plans of adopting EarlySense’s contact free monitor into its smart hospital bed, Centrella.

Market Segmentation

The global Automated Hospital Beds Market segmentation is based in terms of type, type of treatment, technology, usage, and end-user.

By type, the market divides into semi-automatic and fully-automatic hospital beds.

By technology, the market segments into smart automated and basic automated hospital beds.

By type of treatment, the market includes acute care, critical care, and long-term care.

By usage, the market comprises of delivery/birthing, general purpose, pediatric, intensive care, psychiatric care, bariatric, pressure relief, and others.

By end-user, the market includes reproductive care centers, hospitals & clinics, home users, dentistry, and others.

Regional Analysis

The global hospital beds manufacturers is regionally segmented into the following key regions: North America, Asia Pacific, Europe, and the Middle East & Africa.

The European region held the largest share of the global automated hospital beds market as per the last research conducted in 2016. The valuation of the region stood at USD 177.5 million back then. The market standing of Europe can be attributed to factors such as high healthcare expenditure, well-established infrastructure in healthcare, and the active presence of leading players.

The North American region held the second-largest share in the global automated hospital beds market. The market is expected to grow in significant fashion during the assessment period as per the recent report published by MFRF. The growth of the region can be attributed to the well-established healthcare industry and a growing investment towards improving the infrastructure of hospitals. Add to this, continuous encouragement and support from the government to improve the hospital infrastructure in this region is a positive sign that is expected to boost the growth of the market.

Asia Pacific is another essential region in the global standings. The region is expected to garner increasing growth due to the rising number of research and development institutes, growing demand for cost-effective automated hospital beds, and an increasing number of hospitals in this region.

Finally, the Middle East & Africa region is anticipated to show steady and decent growth in the forthcoming years unlike the other booming regions mentioned above. The region is driven by the less availability of innovative healthcare technologies and lack of availability of innovative healthcare technologies.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Cancer Registry Software Market Global Market by Treatments, Causes, Drugs and Diet 2022-2027

 Market Insights

Cancer registry software is a programmed tool of a directory that creates and maintains end-to-end reporting of cancer incidences. It is majorly used to get an overview of certain cases while investigating cancer and its causes. According to Market Research Future, the global cancer registry software market reached $56.4 Million in 2022 and is predicted to attain a CAGR of 10.7% during the forecast period, 2022-2027

Extraordinary breakthroughs and penetrations of science and technology are evolving radically and restructuring the practice of medicine. Aging population, growing middle spending abilities on healthcare, the burden of chronic disease is transforming the patient needs. However, these factors are stimulating new demands dedicated to innovation and access to advanced tools that deliver reliable patient data and comprehensive report of every stage in treatment.

Novel technologies such as predictive modeling for medical procedures are set to flourish owing to growing investment in R&D activities in the field of clinical and molecular data. Growing trend of using data analytics to create reference case study for futuristic clinical operations is likely to propel the global cancer registry software market.

Major Players

Industry leaders are keenly focusing on the development of convenient and accessible solutions for handling critical data related to cancer. Some of the leading players contributing with their product and services include McKesson Corporation, Electronic Registry Systems, Inc., IBM, C/Net Solutions, Himagine Solutions Inc, Rocky Mountain Cancer Data Systems, Ordinal Data Inc, Conduent Inc, Elekta AB (PUB), and Onco, Inc.

Market Segmentation

The global Cancer Registry Software Market is broadly segmented based on the factor such as type, deployment model, database, functionality, and end-user.

The type segment is bifurcated into standalone software and integrated software.

Based on the deployment model, the global cancer registry software market is divided into on-premise and cloud-based.

Similarly, the database type segment is classified into public and commercial.

On the basis of functionality, the global cancer registry software market is segmented into product outcome evaluation, patient care management, medical research, clinical studies, and reporting to federal regulations.

Moreover, the end-user segment is diversified into hospitals, government organizations, medical practitioners, pharmaceutical, research centers, medical device companies, and biotechnology.

Regional Analysis

Geographically, the Americas is expected to influence the global cancer registry software market owing to the growing focus on high-tech product development, growing investment for R&D in region.  As per National Cancer Institute, approximately 1,735,350 new cases of cancer were registered in the US, in 2022.

Europe ranks second after the Americas owing to funding availability and existence of robust research and academic institutes in the region. The European cancer registry software market is anticipated to register a considerable growth during the forecast period.

Moreover, emerging pharmaceutical industry due to low manpower cost and favorable trade conditions in developing markets such as India and China are foreseen to speed up the growth of cancer registry software market in Asia Pacific. A growing number of cancer patients in these regions in contrast to the escalating population makes it mandatory to keep a track on every cancer patient and their diagnostic data.

The Middle East & Africa has the least contribution in the global cancer registry software market and is anticipated to see a moderate growth owing to rising government initiatives for healthcare sectors.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Hemostasis and Tissue Sealing Agents Market Analysis, Study and Pipeline Review 2022

 Market Highlights

The global hemostasis and tissue sealing agents market is projected to grow at a CAGR of 8.6% over the forecast period. There has been increasing demand for such products as it reduces complication during surgical procedures. Moreover, large number of surgical procedures across the globe are impacting the growth of the market positively. Increasing numbers of surgery procedures worldwide is one of another reason for driving the growth of the hemostasis and tissue sealing agents market.  Surgeries are performed by making cut on the body which leads to the wound formation. Hemostasis and tissue sealing agents products are used in external surgical processes for reducing bleeding. For example, they are used in neurosurgical procedures, cardiac surgery, bariatric surgery, leg surgery, cesarean and orthopedic surgery. Hemostasis and tissue sealing agents products, are frequently used to reduce complexity and reduce recovery time after surgery. The high surgical procedure numbers lead to rising need for hemostasis and tissue sealing agents which reduces the risk during surgical procedures. However, factors such as increasing advancement minimally invasive procedures, lack of reimbursement for these products is hampering the growth of the market

Key Players

Some of the prominent players in the global hemostasis and tissue sealing agents market are Johnson & Johnson, Cryolife, Inc., Baxter International, Inc, Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc, Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc and others.

Segmentation

The global Hemostasis and Tissue Sealing Agents Market has been segmented into product, and end user.

By product, the market has been segmented into topical hemostats, and adhesive & tissue sealant. Furthermore, topical hemostats is divided into Active, mechanical (collagen based hemostats, cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats) Flowable. Adhesive & tissue sealant is further segmented into synthetic, natural, and adhesion barrier.

Further on the basis of end user the market is bifurcated into hospitals, ambulatory centers and others

Regional Analysis

Geographically, the Americas is anticipated to dominate the global hemostasis and tissue sealing agents market owing to the high clinical R&D budgets by both government as well as public and private organizations, presence of major manufacturers for the products, high number of surgical procedures and various others. For instance, according to the Center for Diseases Control and Prevention, approximately 46.5 million surgical procedures are performed every year in the U.S.

Europe is expected to hold the second largest position in the global hemostasis and tissue sealing agents market. The hemostatic agent market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increased medical tourism for surgical procedures, increasing healthcare expenditure in developing countries and various others. The Middle East & Africa has the lowest share of the global hemostasis and tissue sealing agents market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Anti-Hypertensive Drugs Market Analysis, Study and Pipeline Review 2022

 Market Scenario for Global Anti-Hypertensive Drugs Market:

Anti-hypertensive drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. 

The global anti-hypertensive drugs market was valued at $32.2 billion in 2015, and is expected to reach $ 38.9 billion by 2022. Thus the antihypertensive medication market is expected to perform sluggish growth at a CAGR of 2.73% from 2018 to 2022.

The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.

Key Players for Global Anti-Hypertensive Drugs Market:

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc.

Segments Global Anti-Hypertensive Drugs Market:

Global anti-hypertensive drugs market has been segmented on the basis of pharmacological class, hypertension type, disease source and Region.

Study Objectives Global Anti-Hypertensive Drugs Market:                  

To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global anti-hypertensive drugs market

To provide insights about factors affecting the market growth      

To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

To provide country level analysis of the market with respect to the current market size and future prospective.

To provide country level analysis of the market for segments and sub-segments.

To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Regional Analysis Global Anti-Hypertensive Drugs Market: 

Globally North America is the largest market for global anti-hypertensive drugs. Europe is the second-largest market for global anti-hypertensive drugs.

The near future market for anti-hypertensive drugs will be dominated by the developed regions with developing regions providing a supporting role only.

However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Bone Wax Market Key Factor, Major Region Analysis and Forecasts Till 2027

 Market Highlights

Bone wax is a mechanical hemostat used in surgeries to stop bleeding. Bone wax does not involve any pharmacological action. It is basically a sterilized mixture of beeswax and it consists of isopropyl palmitate, which is a wax softening agent and is used to stop bleeding from the bone surface. It is used in surgical procedures like orthopedics, thoracic surgery, neurosurgery, dental, oral, traumatology, and jaw surgery. The rising number of surgical procedures is a major booster which drives the global bone wax market. Orthopedic surgeries are increasing due to the rising prevalence of orthopedic diseases, especially osteoporosis and accidental fractures. Also, the rising usage of absorbable bone wax products and the growing geriatric population is also fueling the market growth. According to the Population Reference Bureau in 2016, the number of Americans aged 65 and older is projected to reach 98 million by 2060. On the other hand, stringent government rules for the approval of bone wax and the availability of alternatives for bone wax may hinder the growth of the market during the forecast period.

The global Bone Wax Market Size Key Players is currently dominated by many market players. The prominent market players are engaged in new product launches and strategic partnerships to strengthen its market position. For instance, in February 2016, Wound Management Technologies announced the US Food and Drug Administration (FDA) clearance for its product HemaQuell, which is a resorbable bone wax.

Key Players

Some of the key players in the global Bone Wax Market Key Players are ABYRX Inc., Wound Management Technologies Inc., Aesculap Inc., Ethicon Inc., Medtronic plc, Baxter International, Medline Industries Inc., Futura Surgicare Pvt. Ltd., CP Medical Corp., Bentley Healthcare Pvt. Ltd.,  WNDM Medical Inc., GPC Medical Ltd., and others.

Segmentation

The global Bone Wax Market has been segmented into product, material, application, and end user.

The market, on the basis of product, has been segmented into absorbable bone wax and non-absorbable bone wax.

The market, by material, has been segmented into natural bone wax and synthetic bone wax.

The market, by applications, has been segmented into neurosurgery, orthopedic surgery, thoracic surgery, oral surgery, and others.

The market, by end-users, has been segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.

Regional Analysis

The market in the Americas is expected to dominate the global bone wax market during the forecast period owing to the increasing awareness among the people regarding bone wax and rising orthopedic surgeries. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, increasing prevalence of bone diseases, and growing number of accident and injuries. According to the Arthritis Research UK in 2016, around 10 million people in the UK had a form of arthritis. Moreover, the market in Asia-Pacific region is anticipated to be the fastest-growing during the assessment period owing to the increasing awareness about surgical procedures requiring bone wax, increasing geriatric population, and rising healthcare expenditure. The market in the Middle East & Africa is likely to account for the smallest share of the global bone wax market due to the slowly growing healthcare infrastructure mainly in the African region.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Needle Free Injection Market Key Factor, Major Region Analysis and Forecasts Till 2027

 Needle Free Injection Market Overview:

The global needle free injection market size is expected to touch USD 25,057.4 million by 2027 owing to high prevalence of diabetes and chronic diseases. Market Research Future’s (MRFR) latest study reveals that the market is predicted a 15.28 % CAGR during the forecast period (2022–2027). Needle free injections are medical devices which deliver drugs directly via the skin instead of using hypodermic needles as a medium. High demand for needle less injections in home healthcare in North America and Europe is expected to augur market growth. In addition, rising investments in biopharmaceuticals are expected to provide the market a much-needed impetus.

Awareness among patients regarding benefits of needle free injections is anticipated to prevent reuse of needles and reduce the probability of contamination. Increasing use of these injections by patients owing to its accurate dosage, pain relief, and low risks can lead to high market demand in the coming years. But high costs of these medical devices can pose a challenge to market growth.

Market for Needle Free Injection – Competitive Dashboard

Some of the key players profiled in the market report PenJet Corporation, European Pharma Group, Endo Pharmaceuticals Inc., PharmaJet, Inc., National Medical Products Inc., INJEX Pharma GmBH, Valeritas Holdings, Inc., CROSSJECT, Antares Pharma Inc., MIKA MEDICAL CO., Inovio Pharmaceuticals Inc., Medical International Technology, Inc., and D'Antonio Consultants International, Inc. Investments in research and development and launch of new products are strategies employed by these players to acquire a larger market share.

Global Market for Needle Free Injection – Segmental Analysis

MRFR’s report offers a detailed segmental analysis of the Needle Free Injection Market based on product, technology, usability, type of medication, site of delivery, application, and end-user. By product type, the market has been segmented into fillable and prefilled needle free injectors. The fillable segment is expected to be the biggest product till 2027, with the syringe being beneficial to the practitioner, with the vaccine filled according to the disease. Technologies covered in the report include laser-powered, jet-based, and spring-based. Among these, the jet-based segment can touch a size of USD 10,391.3 million by 2027 owing to a faster method of delivery as compared to other technologies. By usability, the market is segmented into reusable and disposable. The reusable segment is expected to register a 15.90% CAGR over the forecast period.

By type of medication, the market is segmented into projectile/depot-based, powder-based, and liquid-based. The liquid-based segment held a large share of the market in 2022. It can continue to dominate till 2027 owing to its easy working mechanism. By site of medication, the market is segmented into intradermal, intramuscular, and subcutaneous injectors. The intramuscular segment is touted to generate maximum revenue for the needle free injection market owing to muscles absorbing vaccines at a much higher rate as compared to veins.

Applications include oncology, vaccination, and insulin delivery. The insulin delivery segment is projected to expand at a 14.9% CAGR over the forecast period fueled by large pool of diabetics demanding a pain-free solution for receiving insulin. Major market end-users include hospitals and clinics, ambulatory surgical centers, and homecare settings. The hospitals and clinics segment is projected to generate maximum revenue for the market by 2027 owing to high demand for sophisticated devices to deliver vaccines for chronic diseases.

Regional Outlook

The needle free injection market, on the basis of region, is segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). The Americas are expected to dominate the global market owing to prevalence of chronic diseases and demand for self-administrative devices. Technological breakthroughs in pharmaceutical and biotechnology sectors, investments by industry participants, and high awareness among patients are factors anticipated to fuel market growth over the forecast period.

Europe is expected to register a significant growth rate over the forecast period due to the presence of well-established healthcare infrastructure and huge patient pool.

The APAC needle free injection market is projected to showcase a robust CAGR over the forecast period owing to strong economies of India and China. Increased healthcare expenditures of these developing economies coupled with a large patient pool can spur market demand. Enhanced safety and quality standards adhered by manufacturers of these medical devices can culminate in remarkable product sales.

The MEA market commands a smaller market share compared to others owing to stringent government policies and less emphasis on healthcare expenditure.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Thoracic Outlet Syndrome Market SWOT Analysis, Key Players, Analysis and Forecasts Till 2027

 Market Highlights:

 Thoracic outlet syndrome is the compression of the neurovascular structures caused due to weight lifting, tumors in the chest, bone abnormalities, trauma, and others.

A number of factors such as rising cases of road traffic injuries, increasing cases of anatomical defects, high unmet needs of current treatment, and surge in the research and development expenditure, improvement in reimbursement policies are propelling the growth of the global thoracic outlet syndrome market.

However, difficult diagnosis, lack of infrastructure in the middle and low-income countries, and side effects associated with the drugs may hamper the growth of the market over the review period.

It is estimated that thoracic outlet syndrome market is expected to grow at a CAGR 7.0% during the forecast period of 2022-2027.

Key Players:

Some of key the players in the market are Abbott Laboratories, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Endo Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Mallinckrodt plc., Orient Pharma Co., Ltd., Par Sterile Products, LLC., Sanofi, SteriMax Inc., Upsher Smith Laboratories, Inc., Vertical Pharmaceuticals LLC, and others.

Segmentation:

The Thoracic Outlet Syndrome Market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into neurogenic thoracic outlet syndrome, venous thoracic outlet syndrome, and arterial thoracic outlet syndrome.

On the basis of diagnosis, the market is segmented into nerve conduction studies, vascular studies, chest X-ray, cervical spine X-rays, computed tomography (CT) scan, magnetic resonance imaging (MRI), and magnetic resonance imaging with angiography (MRA), arteriogram/venogram, and blood tests.

On the basis of treatment, the market is segmented into surgery, medications, physical therapy, and others. The medications segment is further classified into muscle relaxant, thrombolytic medications, anticoagulant medications, and others.

On the basis of end-user, the market is segmented into hospital & clinics, diagnostic centers, academic and research institutes, drug pharmacies, and others.

Regional Analysis:

The Americas dominate the thoracic outlet syndrome market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is accounted by people with chronic health conditions in the United States.

Europe holds the second position in the thoracic outlet syndrome market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.

Asia Pacific is the fastest growing in thoracic outlet syndrome treatments, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-15.

The Middle East & Africa has the lowest market for thoracic outlet syndrome due to lack of technical knowledge and poor medical facilities.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Muscle Stimulator Market Share Analysis, Strategies, Revenue and Forecasts to 2027

 Market Highlights

The muscle stimulators use electric current to elicit contraction in muscles or nerves. The electric signal has intensity and frequency which mimics the nerve signal system.

The muscle stimulator market is also witnessing high technological development. The manufacturing of medical devices in general and muscle stimulators in particular is also undergoing changes. The latest FDA Approved Muscle Stimulators technological advancements include active research in frequencies and strength of electric current used for muscle stimulation. Increasing miniaturization and portability of the muscle stimulator devices is another development that is driving the growth of the market.

Market fragmentation and falling profit margin are significant threats to the market. The rise of low cost manufacturing economies such as China are challenging the high-tech segment. The muscle stimulators market credibility is being challenged by the rise of spurious low-quality products. There has been cases of burns and skin irritation due to improper use of these low-quality muscle stimulators.

The Muscle Stimulator Market is also becoming more customer oriented and there is increasing demand for personalization and customization which has created the demand for smart muscle stimulators. The muscle stimulators today are a far cry from what they use to be. The latest hi-tech muscle stimulators use the advanced software’s which can set the device into a predefined cycle with suitable shifts. The latest muscle stimulators have started getting synchronized with mobiles. Mobile apps will eventually contain all the data in one single point. Connected healthcare muscle stimulators seems to be the future due to their cost reducing effect and the ability to converge data at a single point for analysis.

Global Muscle stimulator Market Players:

Key players profiled in the report are DJO Global, Inc., Mettler Electronics Corp., Axiobionics, Zynex, NeuroMetrix, Inc., OMRON Corporation, Tone-A-Matic.

Test the market data and market information presented through more than 50 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Muscle stimulator Market” Research Report – Forecast to 2027.

Segmentation:

The global muscle stimulator market is segmented on the basis of products. Based on the products, the market has been segmented as transcutaneous electrical nerve stimulator, burst mode alternating current, neuromuscular electric stimulation, and interferential current. Based on the application, the market has been segmented as pain management, neurological and movement disorder management and musculoskeletal disorder management.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America